Another drug has been added to the toolbox for the treatment of cancer which is known as precision medicine, which aims to treat tumors according to genetic biomarkers and is proving to improve response in patients. this is a oral therapy For a variety of adults and children with locally advanced solid tumor or metastasis These cancers are associated with a genetic alteration present in 1% of patients, but in some rare diagnoses in up to 90% of cases.
Government Hospital: When residents once again rejected the city’s proposal, the fury deepened
In the presentation of the results obtained yesterday larotectinib and was broadcast at the last annual congress of european society for medical oncology (ESMO, for its acronym in English), spokesperson for BayerThe producing laboratory reported that with the recent approval unapproved This new drug includes a therapeutic option for patients with pediatric solid tumors, sarcomas, thyroid, lung, gastrointestinal or skin (melanoma), “as long as they have the same genetic modification, which is known to be involved in more than 20 types of cancer.” has been described.
He estimated that there would be about 100 cancer patients who would meet these laboratory requirements to pinpoint new therapies each year.
This amendment is known as Fusion in the NTRK gene, Among tumors that appeared to be caused by this genetic mutation, according to the company, the typical response was 67% in adult patients and 87% in pediatric patients. The drug, administered via a capsule or a liquid solution, “does not work on one type of tumor, but on a large number of tumors that express the same genetic abnormality,” he explained. Hector MirandaMedical director of the pharmaceutical division of Bayer Southern Conn, on an approved indication for advanced disease with or without metastasis to an organ.
Genetic tests indicated for cancer patients to determine certain tumor characteristics that allow better definition of disease and treatment, allow the identification of specific biomarkers for which treatments already exist in the field of precision medicine. In these tests, some have tested positive for cancer. Fusion of the neutrophilic receptor tyrosine kinase gene (NTRK, from its name in English).
Those genes—NTRK 1, 2 and 3— may merge with another gene and cause abnormal protein formation (TRK fusion proteins) that alter cell growth so that it becomes uncontrolled and favors the appearance of tumor cells.
Urban Innovation: This will be the pedestrian bridge connecting the city of Buenos Aires with Vicente López
Also involved in the presentation in a hall of a hotel in the city of Buenos Aires adriana roseOncologist AT Garhan HospitalYou Edith GrinszpancholseyPresident of Fundación Natalie Dafne Flexer, According to Rose, approximately 1,350 child cancers are diagnosed in the country each year and it is the second leading cause of death among children and adolescents aged one to 15 years. 80% are treated in the public sector; Grahan receives 520 out of all the annual cases.
“With advances in chemotherapy, radiotherapy, surgery and diagnostic support, 80% of children can be cured. But the percentage of patients remains locally advanced, unresectable, metastatic, or relapsed or refractory tumors, This subgroup needs other types of treatments,” the pediatrician said.
Referring to precision medicine, he explained that advances in this field “created a revolution in health as it was possible to begin to conduct genetic and molecular profiling of patients and to adopt personalized treatment. Progress has been made with: the patients who have access are a very heterogeneous population, the treatments they are subsequently given are also very diverse and basically, access to these treatments is difficult”.
He insisted that larotectinib It is the second of three drugs approved for genomic, not histological, targets being incorporated into cancer treatment. He defined it as “an innovative therapy for solid tumors”. [con fusión NTRK] It occurs in both adults and children and occurs in about 20 types of cancer. This is a step forward in the use of a drug that is less toxic and with a better quality of life for the patient.”